Prescription Weight Loss Medications in the UK: Eligibility and Access

Weight loss medications in the UK require a prescription and are subject to NICE eligibility criteria. Understanding which medications are available, what evidence supports them, and how to access them through NHS or private routes prevents both under-use (in people who would significantly benefit) and misuse (of medications not appropriate for the individual).

Why Medications Are Sometimes Appropriate

NICE CG189 (Obesity: identification, assessment and management, 2014, updated 2023) identifies pharmacological intervention as appropriate when:

• BMI is ≥30 (or ≥27 with significant weight-related comorbidities)
• Dietary and lifestyle interventions have been attempted and have not produced adequate weight loss (typically 3–6 months of structured lifestyle programme first)
• The medication is used alongside, not instead of, dietary and lifestyle changes

Weight management medications are not substitutes for behavioural change — they are adjuncts that make the same behavioural changes more effective, or that lower the weight setpoint at which appetite hormones resist further loss.

Licensed Weight Loss Medications in the UK (2025)

Orlistat (Xenical 120 mg prescription; Alli 60 mg OTC)

Mechanism: Pancreatic and gastric lipase inhibitor. Prevents absorption of approximately 30% of dietary fat by blocking the enzyme that breaks triglycerides into absorbable fatty acids. Unabsorbed fat is excreted in stools.

Evidence: Davidson et al. (1999, JAMA, RCT, n=892, 2 years): orlistat + reduced-calorie diet produced 4.2 kg greater weight loss than placebo over 2 years. Torgerson et al. (2004, XENDOS trial, n=3,305, 4 years): orlistat reduced progression from prediabetes to T2D by 37%.

Weight loss: Approximately 3–5% additional loss over placebo at 12 months. Modest but meaningful for metabolic risk reduction.

Side effects: Steatorrhoea (fatty, oily stools), oily anal leakage, faecal urgency — especially when fat intake is high. These are less severe with a reduced-fat diet (which is also required for effectiveness). Fat-soluble vitamin absorption is reduced — supplementing vitamins A, D, E, and K is recommended.

NICE eligibility: BMI ≥30 (or ≥27 with comorbidity). Prescribed at GP level; typically first-line pharmacological option in NHS primary care.

NHS access: Available on prescription free to eligible patients. Alli (60 mg) is available OTC at pharmacies at lower cost but with approximately 50% of the prescription-dose effect.

Liraglutide (Saxenda — 3.0 mg/day injectable)

Mechanism: GLP-1 receptor agonist. Mimics glucagon-like peptide-1 (a gut hormone), slowing gastric emptying and reducing appetite through hypothalamic signalling. The weight management dose (3.0 mg) is higher than the diabetes dose (Victoza: 1.2–1.8 mg).

Evidence: SCALE trial (Pi-Sunyer et al. 2015, NEJM, RCT, n=3,731, 56 weeks): liraglutide 3.0 mg produced 8.4% mean weight loss vs. 2.8% with placebo. 63% of liraglutide participants lost ≥5% body weight vs. 27% placebo.

Administration: Self-injection with a pre-filled pen, once daily, titrated up over 5 weeks to reduce GI side effects.

Side effects: Nausea, vomiting, constipation, diarrhoea — common early, usually reduce with time. Rare: pancreatitis risk (contraindicated with personal or family history of medullary thyroid carcinoma).

NICE eligibility (TA664, 2020): BMI ≥35 with non-diabetic hyperglycaemia (prediabetes HbA1c 42–47 mmol/mol); or BMI ≥30–34.9 when other metabolic criteria are met. Must be prescribed by specialist weight management service (Tier 3) or specialist diabetes service, alongside intensive lifestyle management.

NHS access: Through Tier 3 specialist obesity or diabetes services; not typically prescribed in primary care. Private prescription available from specialist clinics; typically £200–300/month at NHS list price (varies by provider).

Semaglutide (Wegovy — 2.4 mg/week injectable)

Mechanism: GLP-1 receptor agonist (same class as liraglutide but longer-acting, administered once weekly). Acts on hypothalamic appetite centres and slows gastric emptying.

Evidence: STEP 1 trial (Wilding et al. 2021, NEJM, RCT, n=1,961, 68 weeks): semaglutide 2.4 mg produced 14.9% mean weight loss vs. 2.4% placebo — the largest weight loss RCT result for any oral or injectable treatment at the time of publication.

Administration: Once-weekly subcutaneous injection with a pre-filled pen; titrated over 16 weeks.

Side effects: Nausea, vomiting, constipation, diarrhoea — more common in early weeks. Rare: pancreatitis, gallbladder disease.

NICE eligibility (TA875, 2023): BMI ≥35 (or ≥30 in specific ethnic groups with lower BMI thresholds) plus at least one weight-related comorbidity (T2D, hypertension, dyslipidaemia, obstructive sleep apnoea). Must be used alongside a reduced-calorie diet and increased physical activity within a specialist weight management service. Maximum 2 years (after which NICE recommends reassessing if continued treatment is required).

NHS access: Through NHS specialist weight management services (currently rolling out via NHS England's specialised weight management programme). Significant NHS access constraints currently — waiting lists in most areas. Private prescription: approximately £200–250/month.

Tirzepatide (Mounjaro — up to 15 mg/week injectable)

Mechanism: Dual GIP/GLP-1 receptor agonist. Activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor — providing additive or synergistic appetite-suppressing and weight-reducing effects compared to GLP-1 agonism alone.

Evidence: SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM, RCT, n=2,539, 72 weeks): tirzepatide at the maximum 15 mg dose produced 20.9% mean weight loss — the highest documented for any pharmacological intervention in RCTs.

Administration: Once-weekly subcutaneous injection; titrated over 20 weeks from 2.5 mg to maximum 15 mg.

Side effects: Similar to semaglutide — nausea, vomiting, diarrhoea, constipation. May be slightly higher GI side effect frequency at maximum dose.

NICE eligibility (TA1026, 2024): BMI ≥35 with T2D or prediabetes (non-diabetic hyperglycaemia); within specialist weight management or diabetes services.

NHS access: Currently commissioned for specific populations (T2D, high cardiovascular risk); NHS availability expanding. Private prescription: approximately £150–250/month.

What Is Not Available in the UK

Phentermine: A schedule IV controlled stimulant, licensed for obesity treatment in the US but not licensed in the UK. Not legally prescribable in the UK for weight management. Products sold online claiming to contain phentermine or equivalent stimulants are either counterfeit or unlicensed — the MHRA has issued multiple warnings.

Naltrexone-bupropion (Contrave): Not licensed in the UK (licensed in the US and EU as Mysimba). Not available on NHS.

Topiramate-phentermine (Qsymia): Not licensed in the UK.

MHRA Warning on Counterfeit Medications

The MHRA has issued multiple alerts about counterfeit GLP-1 medications (semaglutide, liraglutide) sold online without prescription. Risks include:

• Undisclosed ingredients (some counterfeit products have contained insulin, causing hypoglycaemia)
• Incorrect doses
• Sterility failures (infection risk from injection)

Prescription weight loss medications should only be obtained through registered UK pharmacies with a valid prescription from a registered prescriber (GMC-registered doctor or prescribing pharmacist).

Access Pathway Summary

Disclaimer: This article is for informational and educational purposes only and reflects published NICE guidance as of early 2025. NICE guidance is updated periodically; check NICE.org.uk for current eligibility criteria. Only a GP or specialist can prescribe these medications following individual clinical assessment.